OTC · Healthcare
Cresco Labs Inc. (CRLBF)
As-reported financials and recent SEC filings for Cresco Labs Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$655.8M
Net income
$-135.4M
Net margin
-20.6%
Diluted EPS
$-0.38
ROE
-53.6%
P/E (TTM)
—
Market cap
$300.1M
Debt / equity
1.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $655.8M | $724.3M | $770.9M | — | — |
| Gross profit | $324.6M | $364.5M | $362.4M | — | — |
| Operating income | $-28.0M | $107.3M | $-87.8M | — | — |
| Net income | $-135.4M | $-74.4M | $-175.5M | — | — |
| Diluted EPS | $-0.38 | $-0.22 | $-0.54 | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-05-08
View on EDGAR →40-F2026-03-06
View on EDGAR →6-K2026-02-02
View on EDGAR →EFFECT2025-12-11
View on EDGAR →6-K2025-11-07
View on EDGAR →F-X2025-10-06
View on EDGAR →F-102025-10-06
View on EDGAR →6-K2025-09-22
View on EDGAR →Go deeper on CRLBF
Search Cresco Labs Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.